Doma Perpetual urges Pacira shareholders to vote for its board candidates

DOMA Perpetual Capital Management which, together with its affiliates, beneficially owns approximately 7.5% of the outstanding shares of common stock of Pacira (PCRX) BioSciences, announced that members of DOMA’s three-person slate of nominees for election to the Company’s board of directors have released a joint letter to Pacira stockholders. The letter read, in part, “On May 5, 2026, the Pacira BioSciences board of directors mailed you a letter dismissing us as ‘unqualified,’ characterizing DOMA Perpetual Capital Management, which nominated us for election to the Board, as a disruptive force, and asking you to vote for the Company’s nominees using the Company’s blue proxy card to preserve the status quo. We are writing to give you a clear-eyed view of the questions that letter did not answer, and to make the affirmative case for change. We are independent. We are not employees of DOMA. We each conducted our own diligence on the Company before agreeing to stand for election. What we found is a business with real assets and a worthy non-opioid pain mission, operating inside a governance structure that has not produced the returns or developed the strategic discipline that shareholders deserve. Our purpose, if elected, is to bring fresh perspective and rigorous questioning to the Company boardroom…Even if elected, we would represent only three members of the Pacira board. We are not seeking control. We are seeking the seats necessary to ensure that the full board considers genuine alternatives, asks hard questions, and does so with members whose experience speaks directly to the Company’s risks and opportunities. Shareholders deserve a board willing to confront hard truths, evaluate all options without bias or self-interest, and act decisively to protect and maximize shareholder value. Time and objectivity matter. The board has asked you to disregard DOMA’s proxy statement and WHITE proxy card. We are asking you to read DOMA’s proxy statement, to consider our backgrounds against the specific challenges this company faces, and to decide for yourselves whether a Board that has thus far resisted independent review should be left to evaluate itself. We respectfully request that shareholders vote FOR all three DOMA nominees, Christopher Dennis, MD, MBA, FAPA, Oliver Benton ‘Ben’ Curtis III, and Eric de Armas, using the WHITE proxy card in advance of the June 9, 2026 annual meeting.”